Evoke Pharma (NASDAQ:EVOK) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a report issued on Wednesday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Price Performance

Evoke Pharma stock opened at $4.33 on Wednesday. Evoke Pharma has a 12 month low of $3.54 and a 12 month high of $17.40. The company has a fifty day moving average price of $5.15 and a two-hundred day moving average price of $5.46. The company has a market cap of $6.43 million, a PE ratio of -0.39 and a beta of 0.36.

Institutional Investors Weigh In On Evoke Pharma

A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. purchased a new position in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned 1.42% of Evoke Pharma at the end of the most recent quarter.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.